Corpus Intelligence IC Memo — BEVERLY HOSPITAL 2026-04-26 17:23 UTC
IC Memo — BEVERLY HOSPITAL
Investment Committee Memorandum | CA | 202 beds | Grade C | EBITDA uplift $9.6M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

BEVERLY HOSPITAL

CCN 050350 | LOS ANGELES, CA | 202 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

BEVERLY HOSPITAL is a 202-bed under-performing / distressed in LOS ANGELES, CA with $129.8M in net patient revenue and a -49.4% operating margin. The hospital serves a payer mix of 20.1% Medicare, 7.4% Medicaid, and 72.5% commercial.

Thesis: Undervalued. Our ML models identify $9.6M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -49.4% to -42.0% (+736bps).

Net Revenue HCRIS$129.8M
Current EBITDA COMPUTED$-64.1M
Operating Margin COMPUTED-49.4%
Occupancy HCRIS46.0%
Revenue / Bed COMPUTED$643K
Net-to-Gross HCRIS24.3%
Distress Probability ML50.1%

2. Market Context & Competitive Position

414
CA Hospitals
-4.9%
State Median Margin
223
Comparable Hospitals

CA has 414 Medicare-certified hospitals with a median operating margin of -4.9%. The target's margin of -49.4% places it below the state median. Among 223 size-comparable peers (101-404 beds), the median margin is -4.2%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (101-404), prioritizing same-state peers. 223 hospitals in the comp set.

HospitalStateBedsRevenueMargin
BEVERLY HOSPITAL (Target)CA202$129.8M-49.4%
LUCILE PACKARD CHILDRENS HOSPICA394$2.39B-0.8%
UCI MEDICAL CENTERCA397$1.90B-2.5%
CITY OF HOPE NATIONAL MEDICAL CA217$1.83B-10.7%
RADY CHILDRENS HOSPITAL - SAN CA401$1.82B14.8%
HARBOR-UCLA MEDICAL CENTERCA369$1.54B-6.4%
EL CAMINO HOSPITALCA388$1.34B11.7%
CHILDRENS HOSPITAL OF ORANGE CCA334$1.31B0.7%
KFH - SANTA CLARACA343$1.25B12.5%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $9.6M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$2.7M+210bp18mo
Cost to Collect4.5%2.5%$2.6M+200bp12mo
Denial Rate Reduction12.0%6.5%$2.6M+198bp12mo
A/R Days Reduction5200.0%3800.0%$1.6M+122bp9mo
Clean Claim Rate88.0%96.0%$83K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$2.7M
Cost to Collect
$2.6M
Denial Rate Reduction
$2.6M
A/R Days Reduction
$1.6M
Clean Claim Rate
$83K
Total EBITDA Uplift$9.6M
Current EBITDA$-64.1M
+ RCM Uplift+$9.6M
Pro Forma EBITDA$-54.6M
Current Margin-49.4%
Pro Forma Margin-42.0%
WC Released (1x)$5.0M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-98.7M$-327.5M0.00x-100.0%
Base (11x exit)10.0x11.0x$-98.7M$-392.3M0.00x-100.0%
Bull Case9.0x11.0x$-88.8M$-392.8M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-88.8M$-454.7M0.00x-100.0%
Bear Case11.0x10.0x$-108.5M$-343.2M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-108.5M$-412.8M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
HighElevated distress probabilityModel estimates 50.1% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 223 hospitals with 101-404 beds
  • Same-state prioritization (n=224)
  • Comp margins: P25=-16.7% / P50=-4.2% / P75=4.8%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.